Over the past nine years, patients with spinal muscular atrophy have seen the number of FDA-approved treatment options for ...

Newleos Therapeutics is making its debut with $93.5 million aimed at developing safer and more effective neuroscience ...

Helmed by Roche alums, Newleos Therapeutics is taking over four drugs dropped from the Swiss pharma’s pipeline in early 2024.

Backed by Goldman Sachs, Novo Nordisk’s parent company and others, Newleos Therapeutics debuted Thursday with $94 million and ...

Access to data and to skills specific to AI are among the key challenges pharma companies face to unlock the technology’s ...

1 Day RHHBY 2.56% DJIA 0.77% S&P 500 1.04% Health Care/Life Sciences 0.10% The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...

Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).

Bill Anderson's replacement as chief executive of Roche Pharmaceuticals has been announced, with head of global product strategy Teresa Graham stepping up into the role. Anderson's departure was ...

Blackstone (BX) is planning to secure an $800M loan to finance its acquisition of a stake in a 50-story office building at ...